Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Current Deferred Revenue (2019 - 2020)

Historic Current Deferred Revenue for aTYR PHARMA (ATYR) over the last 2 years, with Q3 2020 value amounting to $53000.0.

  • aTYR PHARMA's Current Deferred Revenue fell 8494.32% to $53000.0 in Q3 2020 from the same period last year, while for Sep 2020 it was $53000.0, marking a year-over-year decrease of 8494.32%. This contributed to the annual value of $208000.0 for FY2019, which is N/A changed from last year.
  • Latest data reveals that aTYR PHARMA reported Current Deferred Revenue of $53000.0 as of Q3 2020, which was down 8494.32% from $201000.0 recorded in Q2 2020.
  • In the past 5 years, aTYR PHARMA's Current Deferred Revenue ranged from a high of $630000.0 in Q1 2019 and a low of $53000.0 during Q3 2020